<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01681264</url>
  </required_header>
  <id_info>
    <org_study_id>2013P-001510</org_study_id>
    <secondary_id>1R01DA036564-01</secondary_id>
    <nct_id>NCT01681264</nct_id>
  </id_info>
  <brief_title>Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance</brief_title>
  <official_title>Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual medication (guanfacine and morphine) as a standard treatment for chronic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This aim proposes that guanfacine would be a useful drug to deter Opioid-Induced Hyperalgesia
      (OIH) when combined with an opioid (morphine) in chronic pain management.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative Sensory Testing (QST)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quantitative Sensory Testing (QST) results will be used to compare the 5 treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heat Pain Threshold</measure>
    <time_frame>12 weeks</time_frame>
    <description>Subjects will be measured for their heat pain threshold using Quantitative Sensory Testing (QST). The testing will be done at 5 of the 6 visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heat Pain Tolerance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Subjects will be measured for their heat pain tolerance using Quantitative Sensory Testing (QST). The testing will be done at 5 of the 6 visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal Pain Summation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Subjects will be measured for their temporal pain summation using Quantitative Sensory Testing (QST). The testing will be done at 5 of the 6 visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detecting Diffuse Noxious Inhibitory Control (DNIC)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Subjects will be measured for their Diffuse Noxious Inhibitory Control (DNIC). The testing will be done at 5 of the 6 visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heat Sensation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Subjects will be measured for their heat sensation using Quantitative Sensory Testing (QST). The testing will be done at 5 of the 6 visits.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Morphine:Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine:Guanfacine 1mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine:Guanfacine 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo:Guanfacine 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo:Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <arm_group_label>Morphine:Placebo</arm_group_label>
    <arm_group_label>Morphine:Guanfacine 1mg</arm_group_label>
    <arm_group_label>Morphine:Guanfacine 2mg</arm_group_label>
    <other_name>MS Contin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine 1mg</intervention_name>
    <arm_group_label>Morphine:Guanfacine 1mg</arm_group_label>
    <other_name>Intuniv</other_name>
    <other_name>Tenex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine 2mg</intervention_name>
    <arm_group_label>Morphine:Guanfacine 2mg</arm_group_label>
    <arm_group_label>Placebo:Guanfacine 2mg</arm_group_label>
    <other_name>Intuniv</other_name>
    <other_name>Tenex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Morphine:Placebo</arm_group_label>
    <arm_group_label>Placebo:Guanfacine 2mg</arm_group_label>
    <arm_group_label>Placebo:Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  18-65 years old

          -  Chronic neck or back pain condition for at least 3 months

          -  VAS score of 4-8

          -  Has not taken an opioid for the last 3 months

          -  Has not taken guanfacine (or other alpha-2AR agonists) for the last 6 months

        Exclusion Criteria

          -  Sensory deficits at site of QST, such as peripheral neuropathy

          -  Allergic to or has had a severe adverse reaction to study medication (i.e. opioids,
             guanfacine, lactose, vitamin B2 a.k.a. riboflavin)

          -  Cannot tolerate study drugs' maximum doses

          -  Takes vitamin B2 &gt; 1.6mg/day during the study

          -  Pregnant or breastfeeding

          -  Pending litigation

          -  Diagnosed with Raynaud's syndrome

          -  Has other chronic pain conditions such as fibromyalgia or joint osteoarthritis that
             are predominant over back and neck pain with regard to its intensity (VAS)

          -  Has known pre-existing cardiovascular disease (i.e. arrhythmia - prolonged QT interval
             &gt; 440ms), cerebrovascular disease, hepatic or renal impairment, CNS condition,
             metabolic condition, or history of syncope

          -  Hypotension (SBP &lt; 90 mmHg and DBP &lt; 60 mmHg for female or SBP &lt; 100 mmHg and DBP &lt; 60
             mmHg for male; measured while in a sitting position) or bradycardia (resting heart
             rate &lt; 60 bpm)

          -  Subjects are on antihypertensive drugs (e.g., a beta-blocker) that result in
             hypotension and/or bradycardia as defined above

          -  Tests positive for non-study opioids, illicit drugs, marijuana, or non-prescribed
             drugs

          -  Major psychiatric disorders that required hospitalization in the past 6 months such
             as: major depression, bipolar disorder, schizophrenia, anxiety disorder, or psychotic
             disorders

          -  Currently in a treatment program for alcohol or drug abuse, or currently on methadone
             or buprenorphine (i.e. suboxone, subutex) for treatment of addiction, or stimulants
             for treatment of ADHD

          -  History of substance or alcohol abuse (meets DSM IV criteria) per medical record or
             subject admission

          -  Subjects are on medications that serve as CYP3A4/5 inhibitors or CYP3A4 inducers
             including, but are not limited to, valproic acid, macrolide antibiotics, antifungal
             drugs, St. John wort, ACE inhibitors, nefazodone (antidepressant), calcium channel
             blockers, H2-receptor antagonists, anti-HIV or AIDS drugs, and antiepileptic drugs

          -  Subjects are on medications that are ligands for alpha2-adrenergic receptors including
             antipsychotic drugs (e.g. clozapine) and tricyclic or tetracyclic antidepressants
             (e.g. imipramine, mirtazapine, mianserin). Any medications taken by a subject at the
             enrollment will be reviewed regarding their compatibility with guanfacine and morphine
             as well as possible confounding side effects. In addition, subjects will be warned of
             side effects of morphine such as sedation, respiratory depression at the enrollment.
             Subjects will be allowed to take non-opioid pain medications except for gabapentinoids
             and amitriptyline/nortriptyline as far as such medications do not have incompatibility
             with morphine and guanfacine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianren Mao, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arissa Opalacz, B.A.</last_name>
    <phone>617-724-6102</phone>
    <email>aopalacz@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Roth, B.S.</last_name>
    <phone>617-724-6102</phone>
    <email>sroth3@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Translational Pain Research</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arissa Opalacz, B.A.</last_name>
      <phone>617-724-6102</phone>
      <email>aopalacz@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Roth, B.S.</last_name>
      <phone>617-724-6102</phone>
      <email>sroth3@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jianren Mao, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massgeneral.org/painresearch/</url>
    <description>Center for Translational Pain Research</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2012</study_first_submitted>
  <study_first_submitted_qc>September 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2012</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jianren Mao, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Pain Management</keyword>
  <keyword>Back pain</keyword>
  <keyword>Neck pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

